Protara Therapeutics Stock (NASDAQ: TARA)

Protara Therapeutics

PROTARA THERAPEUTIC INC

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Crude

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

CGON

GLMD

GRPN

PLUG

SPRB

TARA

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook

Wall Street

Trading Ideas

NAAS

PAPL

Dow Jumps Over 150 Points; Domino&#39;s Pizza Posts Upbeat Earnings

Munich,,Bavaria,,Germany,-,March,31,2023:,H.b.,Fuller,Specializes

Upgrades

Pre-Market Outlook

Analyst Ratings

CSIQ

GNRC

URGN

WRBY

YETI

This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics Inc

Taraxa

Tarachi Gold Corp

TARANIS RESOURCES INC ORD by Taranis Resources Inc.

Taranis Resources Inc

Press Releases

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Health Care

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Management

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Protara Therapeutics to Participate in Upcoming Investor Conferences

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Atossa Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cellectis S.A. - American Depositary Shares

Cellectis

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Korro Bio

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lyell Immunopharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Vigil Neuroscience

Exagen

HC Wainwright & Co.

Scotiabank

LifeSci Capital

Guggenheim

Comments

Protara Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell